In patients with hemodynamically significant pulmonary embolism, physiological fibrinolysis fails to dissolve thrombi acutely and r-tPA (recombinant tissue-type plasminogen activator) therapy may be required, despite its bleeding risk. To examine potential mechanisms, we analyzed the expression of key fibrinolytic molecules in experimental pulmonary emboli, assessed the contribution of α2-antiplasmin to fibrinolytic failure, and compared the effects of plasminogen activation and α2-antiplasmin inactivation on experimental thrombus dissolution and bleeding.
P ulmonary embolism (PE) affects millions of patients each year and is a leading cause of hospital mortality. [1] [2] [3] Physiological or endogenous fibrinolysis usually fails to dissolve pulmonary emboli that may cause acute obstructive complications such as hypotension and shock. The persistence of thromboemboli also may lead to serious complications like chronic thromboembolic pulmonary hypertension and right ventricular dysfunction. 4 Anticoagulation is the standard therapy for PE, but anticoagulation only prevents new thrombus formation on preexisting thromboemboli and does not cause thrombus dissolution. 5 In patients with massive PE, pharmacological, r-tPA (recombinant tissue-type plasminogen activator) therapy is given to rapidly dissolve thromboemboli to enhance hemodynamic function, relieve hypotension and reduce mortality. 6, 7 However, treatment with r-tPA and other plasminogen activators causes serious bleeding that restricts its use to patients with massive PE who have a high risk of mortality. 6, 7 Why endogenous fibrinolysis fails to dissolve acute pulmonary emboli is not well understood. Studies using genetically modified mice and inhibitors have shown that tissue-type (t) 8 and urinary-type (u) plasminogen activator (PA), 9 which convert plasminogen to the active enzyme plasmin, contribute to the dissolution of experimental pulmonary emboli. In a similar fashion, their inhibitor, plasminogen activator inhibitor-1 (PAI-1) suppresses fibrinolysis. 10 The plasmin inhibitor α2-antiplasmin 11, 12 affects the dissolution of experimental pulmonary emboli and epidemiological studies in humans identify higher α2-antiplasmin levels as a risk factor for venous thromboembolism. 13 Whether these components of the fibrinolytic system are expressed at the site of acute pulmonary emboli is unknown. Similarly, little information exists about the relative contribution of the endogenous plasminogen activation and plasmin inhibition, and their interactions, to the rate and extent of fibrinolysis in vivo. Finally, it is uncertain whether promoting fibrinolysis by selectively altering plasminogen activation or plasmin inhibition has the same downstream effects on coagulation and bleeding.
We examined the expression of the plasminogen activation and plasmin inhibition system at the site of experimental pulmonary emboli. We compared the effects of plasminogen activation with α2-antiplasmin inactivation on experimental fibrinolysis, fibrinogen levels, and bleeding. Experimental α2-antiplasmin inactivation enhances endogenous fibrinolysis to levels comparable to levels achieved with higher-dose r-tPA, but unlike r-tPA, does not cause fibrinogen destruction or enhance surgical bleeding. These data suggest that plasmin inhibition by α2-antiplasmin is a key rate-limiting step in the acute dissolution of experimental pulmonary emboli.
METHODS

Proteins and Reagents
Reagents were purchased from the following sources: human α2-antiplasmin (Athens Research and Technology); human plasmin (Calbiochem); bovine thrombin (Sigma); citrated frozen human plasma (Lampire Biological Laboratories); chimeric α2-antiplasmin-inactivating antibody (TS23, Translational Sciences); 125 I-fibrinogen (Perkin-Elmer); fluorescein isothiocyanate-fibrinogen (Molecular Innovations); r-tPA (Alteplase, Genetech Inc.); and all the other reagents, if not specified (Sigma).
Pulmonary Embolism
Animal studies were approved by the Institutional Animal Care and Use Committee. The dissolution of experimental pulmonary emboli, fibrinogen degradation, and bleeding were examined in a humanized model, in which adult male and female α2-antiplasmin -/-mice (KOMP, UC Davis) on a C57Bl/6 background were supplemented with physiological amounts of human α2-antiplasmin. To prepare plasma clots, pooled fresh frozen human plasma (5 µL) was mixed with trace amounts of 125 I-fibrinogen (≈5000 cpm), 0.25 U/mL (NIH units) bovine thrombin, and 100 mmol/L CaCl 2 in a total clot volume of 12.5 µL. After overnight incubation at 37°C, the clots were compressed, washed thoroughly with saline, and cut into 20 pieces before embolization. Mice were anesthetized by ketamine, xylazine, and atropine and kept on continuous anesthesia during the surgery. An anterior midline incision was made in the neck, and the left jugular vein was exposed. A small incision was made in the jugular vein and a nonocclusive PE-10 catheter was inserted. Human α2-antiplasmin (4.7 mg/kg) was promptly infused intravenously to achieve physiological levels. Then, clots in saline were embolized into the lungs through the PE-10 catheter. After 30 minutes,
Clinical Perspective
What Is New?
• Acute, experimental pulmonary emboli resist dissolution although they contain key components of the fibrinolytic system. • Monoclonal antibody inactivation of α2-antiplasmin, an endogenous inhibitor of plasmin, effectively dissolves pulmonary emboli with similar potency to high-dose r-tPA (recombinant tissue-type plasminogen activator).
• α2-Antiplasmin inactivation synergizes with low-dose r-tPA to enhance thrombus dissolution.
• Unlike r-tPA, α2-antiplasmin inactivation alone or in combination with low-dose r-tPA does not cause fibrinogen degradation or increase bleeding.
What Are the Clinical Implications?
• α2-Antiplasmin is a dominant regulator that prohibits thrombus dissolution in vivo.
• Therapeutic modulation of α2-antiplasmin activity may prove an effective strategy to enhance fibrinolysis without significantly increasing the bleeding risk.
various treatment agents such as r-tPA (0.1-3.0 mg /kg), human α2-antiplasmin-inactivating antibody (α2-antiplasmin-I; 10 mg/kg), and a combination of r-tPA + α2-antiplasmin-I were given intravenously. Tail bleeding was measured after PE as described below. After 4 hours of PE, the mice were euthanized, blood was collected for plasma preparation from cardiac puncture, and the heart and the lung tissue were harvested for further study.
Immunohistology studies of PE were performed in wildtype, α2-antiplasmin +/+ mice (C57Bl/6, Jackson Labs) and human clots were labeled with fluorescein isothiocyanate-fibrinogen instead of 125 I-fibrinogen as described. Four hours after PE, the mice were euthanized and the lungs were perfused with saline and isolated for immunofluorescence staining as described below.
Measurement of Thrombus and Clot Dissolution
To assess thrombus dissolution in vivo, the radioactive content of the clots in the catheter before embolization was measured in a gamma counter before clot injection. The total radioactivity of the injected thrombus was determined by subtracting the radioactivity remaining in the injection tubing after embolization. After 4 hours, the heart and lungs were isolated and the total remaining pulmonary and vascular radioactivity was measured by gamma scintillation counting. The percentage of thrombus dissolution = 100% × (total thrombus cpm -residual thrombus cpm)/(total thrombus cpm).
To measure clot dissolution in vitro, clots were formed by mixing together in a 5-mL Sarstedt tube, 20 µL of human plasma with or without α2-antiplasmin-inactivating antibody (1.4 µg, 0.25 µL, 100 nmol/L final), trace amounts of 125 I-fibrinogen (0.3 µL, ≈9000 cpm), 10-µL solution of calcium chloride (25 mmol/L), and thrombin (2.5 U/mL) at 37°C for 1 hour. After counting each tube to determine the amount of cpm per clot, the tubes were placed on ice. r-tPA (Activase, Genentech) was added to each tube (70 µL at a concentration of 0.2 nmol/L) including no r-tPA as control. Then 10 µL of supernatant was counted to determine baseline counts. Tubes were incubated at 37°C and 10 µL of the supernatant was removed at 3 hours to measure the release of 125 I-fibrin degradation products by gamma counting in 10-µL samples. The percentage of clot dissolution was determined by dividing the counts per minute of released 125 I-fibrin degradation products by the original 125 I-fibrin associated with the clot and multiplying by 100%.
Tail Bleeding and Hemoglobin Assays
Tail artery and vein bleeding were measured by the tail-tip amputation method ≈2.5 hours (mean, 2.3±0.4 hours) after thromboembolism.
14 In anesthetized mice, tails were prewarmed for 5 minutes in 3 mL of saline (prewarmed) at 37°C. A distal 2-mm segment of the tail was amputated and bleeding was monitored for 30 minutes after reimmersing the tail in 0.9% warm saline tube on the heating pad at an angle of 45°. Total bleeding time was measured as summation of bleeding and rebleeding time recorded for 30 minutes. Total blood in saline was centrifuged and the pellet was dissolved in 3 mL of Drabkin's reagent and measured according to the manufacturer's instructions (Sigma).
Immunofluorescence Staining and Analysis
Lungs were inflated by tracheal infusion of OCT embedding medium (Fisher Scientific), harvested and embedded in OCT medium. Lung cryosections (8 µm) were cut on slides, air dried, fixed in chilled acetone for 10 minutes, and again dried for 15 minutes. After washing in phosphate-buffered saline, sections were blocked with 10% normal donkey serum for 1 hour and incubated with primary antibody in 2% normal donkey serum for 90 minutes at room temperature. After phosphatebuffered saline washings, sections were probed with fluorophore-conjugated donkey secondary antibodies as we have described previously. 15 The primary antibodies include rabbit anti-mouse against tPA (ASMTPA-GF; Molecular Innovations), uPA (urokinase plasminogen activator) (ASMUPA-GF-HT; Molecular Innovations), and PAI-1 (IASMPAI-GF; Innovative Research), rabbit anti-mouse plasminogen (Abcam), goat antimouse α2-antiplasmin (AF1239; R&D Systems), and rat antimouse Ly6G (clone1A8, #127602; Biolegend). Alexa Fluor 555 conjugated donkey anti-rabbit, donkey anti-goat, and goat anti-rat were used as secondary antibodies. 4′,6-Diamidino-2-phenylindole containing Vectashield hardset mounting media (Vector Laboratories) was used to stain cell nuclei. Slides were scanned for fluorescence images with Aperio image fluorescence scanner (AperioScanScope). Images were taken at 20× magnification (100 µm) using ImageScope software to examine the expression levels of tPA, uPA, plasminogen, PAI-1, and α2-antiplasmin at the thromboembolus site, and in distal pulmonary arteries without thrombus, as well. The area of interest in pulmonary arteries (in 100 µm images) with and without thromboemboli were selected and total positive fluorescence area was measured by using Image Pro Plus 6.2 and analyzed in Graph Pad Prism 5.2.
Fibrinogen Assay
Blood samples from the mouse heart were collected in sodium citrate/EDTA to prepare platelet poor plasma. Total fibrinogen was quantitatively determined by sodium sulfite method 16 in the presence of aprotinin (0.4 Trypsin inhibitor unit/mL, SigmaAldrich) as we have described previously. 
α2-Antiplasmin Activity
The effect of α2-antiplasmin on plasmin activity was assessed by examining the cleavage of a paranitroanilide substrate S2251. Purified α2-antiplasmin (20 µL, 60 nmol/L, Calbiochem) was mixed with no antibody or a purified α2-antiplasmin-inactivating antibody or purified control, anti-nitrophenol monoclonal antibody of the same isotype as α2-antiplasmin-inactivating antibody (MCA334B AbD Serotec) (20 µL, 60 nmol/L) at room temperature for 10 minutes. Then assay buffer (20 µL, 50 mmol/L Tris HCl, 100 mmol/L NaCl, pH 7.4) and plasmin substrate S2251 (20 µL, S2251, 0.5 mmol/L, Chromogenix) were added to the wells of a microtiter plate. Plasmin (20 µL, 20 nmol/L, Calbiochem) was added to start the reaction. The cleavage of S2251 substrate was monitored at room temperature in a microtiter plate reader (BIO-TEK, Synergy HT) at A405. Experiments were performed in duplicate, and the amount of plasmin activity was expressed relative to the amount of plasmin activity in the absence of α2-antiplasmin or any antibody. Plasma α2-antiplasmin activity was measured in a similar fashion in duplicate. Plasma samples were treated with methylamine (0.1 mol/L, Sigma) to prevent interference from α2-macroglobulin. 18 Plasma samples were incubated with plasmin (100 nmol/L, Hematologic Technologies, Inc.) and the cleavage of S2251 substrate (0.5 mmol/L) in microtiter plate wells was monitored for 20 minutes in a microtiter plate reader. Plasma samples were compared with a standard curve in which purified α2-antiplasmin was added in 8 different concentrations (0-100 nmol/L) to α2-antiplasmin-deficient plasma. Plasma levels of α2-antplasmin antigen were also measured at different dilutions in α2-antiplasmin -/-mice given α2-antiplasmin by ELISA as directed by the manufacturer (Innovative Research).
Statistical Analysis
Statistical analysis was done in Graph Pad Prism 5.2 software. Data represent the mean±standard error. Normally distributed data were analyzed by an unpaired Student's t-test, a one-way or two-way analysis of variance using the Neuman-Keuls correction. Data that were not normally distributed were analyzed by a Mann-Whitney test or a one way Kruskal-Wallis analysis using the Dunn correction. A 2-tailed P<0.05 was considered statistically significant.
RESULTS
Pulmonary Emboli Contain Plasminogen Activators and Plasmin Inhibitors
When examined 4 hours after thromboembolism, fluorescein isothiocyanate-labeled pulmonary emboli were found adjacent to the tPA-immunostained endothelium in pulmonary arteries ( Figure 1A) ; tPA was also detected in the nonembolized pulmonary arteries, and bronchial arteries, as well, as previously described. 19 Endothelial cell expression of tPA was confirmed by double immunostaining with CD31 (online-only Data Supplement Figure I ). In comparison with tPA, uPA expression was present not only at the margins of the thrombus but also within the pulmonary embolus itself ( Figure 1B and 1D) . In the absence of a thromboembolus, uPA expression was identified in pulmonary arteries, and in extravascular lung tissue, as well, and appeared to be associated with 4′,6-diamidino-2-phenylindole-stained cells. Neutrophils express uPA and the uPA receptor; immunostaining showed that neutrophils could be detected at the margins, and within the body of the pulmonary embolus, as well (online-only Data Supplement Figure II) . In the absence of pulmonary emboli, neutrophils were also found in the lung parenchyma and occasionally in nonembolized pulmonary vessels. Plasminogen expression was increased nearly 10-fold at the thrombus site in comparison with pulmonary arteries without thromboemboli ( Figure 1C and 1D, P<0.001) . Plasminogen was also found in a circumferential pattern on the periphery of 4′,6-diamidino-2-phenylindole-stained cells, suggesting that it may be cell associated (online-only Data Supplementary Figure III) . 20 There was significant enhancement of α2-antiplasmin staining within the pulmonary emboli in comparison with the negligible staining in the pulmonary vasculature without thromboemboli (Figure 2A and 2C, P<0.01) . PAI-1 expression was also detected within the pulmonary emboli, but vascular wall expression at the site of the acute pulmonary embolus did not appear to be increased (Figures 2B and 2C , P = not significant) in comparison with nonembolized pulmonary arteries. Taken together, these data indicate that important components of the fibrinolytic system are present at the site of acute pulmonary emboli.
Effect of α2-Antiplasmin on Endogenous Fibrinolysis in Pulmonary Embolism
Previous studies have shown that in α2-antiplasmindeficient pulmonary emboli injected into α2-antiplasmin -/-mice dissolve at accelerated rates. However, the extent to which α2-antiplasmin continues to dynamically affect endogenous fibrinolysis in existing pulmonary emboli is unknown. To enhance the translational relevance of these findings for human disease, we created a humanized model of PE in α2-antiplasmin-deficient mice. This allowed us to study the effect of human α2-antiplasmin on the dissolution of human embolized clots. Previous studies have shown that human and mouse α2-antiplasmin react similarly to mouse plasmin. 21 Physiological levels of human α2-antiplasmin (mean 58±8 μg/mL, n=4) were achieved in α2-antiplasmin-deficient mice by administration of human α2-antiplasmin, which persisted through the duration of the experiment. When an α2-antiplasmin-inactivating monoclonal antibody was administered 30 minutes after embolization to mice with normal α2-antiplasmin levels, it significantly reduced α2-antiplasmin activity in comparison with the control mice (0.11±0.02 versus 0.92±0.05 μmol/L, P<0.001), but it but did not significantly affect plasma α2-antiplasmin antigen levels (76±7 µg/mL, n=4, P=0.16). The α2-antiplasmin-inactivating antibody enhanced thrombus dissolution ( Figure 3A , P<0.0001) in comparison with control mice with normal α2-antiplasmin levels. In vitro studies confirmed that this antibody neutralized α2-antiplasmin activity in solution ( Figure 3B and 3C ) or bound to fibrin (online-only Data Supplement Figure IV) , preventing inhibition of plasmin catalytic activity. The α2-antiplasmin-I prevented inhibition of plasmin-mediated fibrinolysis, thereby significantly enhancing the dissolution of human clots ( Figure 3D ).
Effects of r-tPA and α2-Antiplasmin-I on Thrombus Dissolution
Although tPA was present at the site of the pulmonary emboli, there was minimal thrombus dissolution in control mice (saline treated) indicating that endogenous tPA activity was insufficient to rapidly dissolve the pulmonary embolus ( Figure 4) . In this humanized model, low-dose r-tPA at 0.1 mg/kg or 0.24 mg/kg did not significantly enhance dissolution of pulmonary emboli in comparison with control mice (Figure 4) . A dose of r-tPA similar to the human clinical dose (1.2 mg/kg) caused a significant enhancement in thrombus dissolution in comparison with control mice (36.3±3.9% versus 16.7±3.4%, P<0.001). The dissolution of pulmonary emboli was further enhanced by high-dose r-tPA (3 mg/kg) (62.3±3.6% P<0.001). PE dissolution induced by α2-antiplasmin-I (10 mg/kg) was greater than observed with 1.2 mg/kg r-tPA (58.3±4.0% versus 36.3±3.9% P<0.001), and it was comparable to that of high-dose r-tPA (62.3±3.6%, 3 mg/kg) ( Figure 4 ).
To determine whether there was a significant interaction between r-tPA and α2-antiplasmin in the regulation of fibrinolysis, the effects of low-dose r-tPA in combination with α2-antiplasmin inactivation were examined. A twoway analysis of variance showed that α2-antiplasmin-I + r-tPA significantly enhanced thrombus dissolution versus r-tPA alone (P<0.0001). The combination of 0.1 mg/kg r-tPA with α2-antiplasmin inactivation (10 mg/kg) significantly increased dissolution in comparison with r-tPA 1.2 mg/kg alone (P<0.001) and the same dose of α2-antiplasmin inactivation alone (P<0.001). The combination of 0.24 mg/kg r-tPA with α2-antiplasmin inactivation also significantly increased thrombus dissolution versus α2-antiplasmin inactivation alone (P<0.01), 1.2 mg/ kg r-tPA alone (P<0.001), and 3.0 mg/kg r-tPA alone (P<0.05). This significant enhancement in fibrinolysis is consistent with synergism between the α2-antiplasmin inactivation and r-tPA in thrombus dissolution.
Effects of r-tPA and α2-Antiplasmin on Fibrinogen Consumption and Bleeding
Therapy with r-tPA is associated with consumption of coagulation factors or fibrinolytic system components, eg, fibrinogen degradation. 22 There was a significant reduction in α2-antiplasmin activity in mice treated with r-tPA (3 mg/kg) versus controls (0.17±0.08 versus 0.92±0.05 μmol/L, P<0.001). Treatment with r-tPA caused a significant increase in fibrinogen degradation of 25% to 57% in a dose-related fashion in comparison with fibrinogen levels in normal, untreated mice ( Figure 5A ). By comparison, α2-antiplasmin-I treatment alone or in combination of α2-antiplasmin-I with low-dose r-tPA (0.1-0.24 mg/kg) did not show a statistically significant change (≤5%) from normal controls ( Figure 5A ). In a two-way analysis of variance, low doses of r-tPA with α2-antiplasmin-I showed significantly less reduction of fibrinogen (P≤0.01) versus low-dose r-tPA alone.
The regulation of endogenous fibrinolysis may affect hemostasis following vessel injury. We compared the effects of α2-antiplasmin inactivation and r-tPA on hemorrhage by using the well-established, tail-bleeding method. Bleeding was increased significantly in mice receiving a clinical dose (1.2 mg/kg, P<0.001) or higher dose (3 mg/kg, P<0.001) of r-tPA in comparison with control I-fibrin-labeled pulmonary emboli was measured in anesthetized α2-antiplasmin (a2AP) -/-mice (n=16) with physiological levels of α2-antiplasmin (after intravenous supplementation) with or without (control) treatment with an a2AP-inactivating antibody (a2AP-I). The percentage of thrombus dissolution was assessed by measuring the residual 125 I-fibrin radioactivity in the lungs 4 hours after embolization. ****P<0.0001 versus control. B, The activity of plasmin in the presence of no a2AP or a2AP, with or without an a2AP-inactivating (a2AP-I), or a control monoclonal antibody of the same isotype (MCA334B0). Plasmin activity was monitored by cleavage of S2251, a paranitroanilide substrate, at A405. Experiments were performed in duplicate, and the amount of plasmin activity was expressed relative to the amount of plasmin activity in the absence of a2AP or any antibody. C, The effect of no a2AP (Control, Ctl) or a2AP with or without various monoclonal antibodies (mAbs) on plasmin activity, expressed as percentage of the activity of plasmin in the absence of a2AP. ***P<0.001. D, Effect of an a2AP-I antibody or buffer alone (control) on dissolution of 
Comparative Effects on Fibrinolysis and Bleeding
Optimal treatment for PE would maximize thrombus dissolution with low bleeding risk ( Figure 6A ). Both r-tPA and α2-antiplasmin are in the fibrinolytic pathway, but it is unknown whether they exert the same effects on clot dissolution and bleeding. Low doses of r-tPA were associated with minimal thrombus dissolution and no increases in bleeding risk ( Figure 6B ). Higher-dose r-tPA (1.2 and 3 mg/kg) increased both thrombus dissolution and bleeding in parallel. In contrast, α2-antiplasmin inactivation alone, or in combination with low-dose r-tPA, led to increased thrombus dissolution with low bleeding risk ( Figure 6B ).
DISCUSSION
These experiments with α2-antiplasmin-deficient mice, α2-antiplasmin replacement, and α2-antiplasmin inactivation showed that the plasmin inhibitor, α2-antiplasmin, suppressed endogenous fibrinolysis after pulmonary embolism. The magnitude of α2-antiplasmin's regulatory effect on fibrinolysis was assessed by α2-antiplasmin inactivation and was comparable to the fibrinolysis achieved with pharmacological doses of r-tPA (3 mg/ kg). There was synergism between low-dose r-tPA and α2-antiplasmin inactivation indicating that α2-antiplasmin modulated the fibrinolytic effects of r-tPA. Although α2-antiplasmin inactivation and higher-dose r-tPA were comparably effective in dissolving thrombi, they showed distinctly different effects on fibrinogen degradation and tail bleeding. Fibrinogen levels were significantly reduced by increasing doses of r-tPA, but not by α2-antiplasmin inactivation. Bleeding was enhanced by fibrinolytic doses of r-tPA but not by α2-antiplasmin inactivation.
To our knowledge this is the first demonstration that all these particular key components of the plasminogen activation and plasmin inhibition systems are expressed at the site of an acute pulmonary embolism. These thrombi also contained neutrophils consistent with an acute inflammatory response. Although increased levels of α2-antiplasmin are associated with an increased risk for human venous thromboembolism by univariate analysis 13 and diagnostic agents carrying the N-terminal peptide of α2-antiplasmin can identify developing venous thrombi, 23 the presence of α2-antiplasmin in acute pulmonary emboli has not been previously identified.
Three component processes contribute to the regulation of endogenous fibrinolysis by plasmin. The first component, plasminogen activation or plasmin generation, is regulated by tPA, uPA, and PAI-1 (and other inhibitors). The second component of plasmin inhibition is mediated by α2-antiplasmin (fast inhibitor) and α2-macroglobulin (slower inhibitor). 24 The third component is modification of the plasmin substrate fibrin by activated factor XIII and thrombin-activatable fibrinolysis inhibitor (TAFI). Although not investigated in the current study, there is evidence that all of these components contribute to fibrinolysis in experimental PE. Gene deletion studies demonstrate that tPA -/-8 and uPA -/-9 mice show reduced dissolution of experimental pulmonary thrombi/microemboli. PAI-1 (PAI-1 -/-), 10 TAFI (TAFI -/-), 25 or α2-antiplasmin (α2-antiplasm in -/-) 11,12 deficiency or α2-antiplasmin inhibition 26 causes enhanced fibrinolytic potential in pulmonary embolism.
A B Figure 5 . Effects of pharmacological r-tPA and α2-antiplasmin inactivation on fibrinogen consumption and bleeding dissolution in mice with experimental pulmonary emboli. A, Fibrinogen consumption in experimental groups given an α2-antiplasmin-inactivating antibody (a2AP-I) or r-tPA or no treatment (Control). Fibrinogen levels were measured by the sodium sulfite method and are expressed relative to fibrinogen levels in normal wild-type mice without pulmonary emboli. B, Tail bleeding was measured as hemoglobin (Hgb) loss by Drabkin reagent in the same experimental groups. n per group is shown. **P<0.01. ***P<0.001 versus controls.
Studies with specific inhibitors demonstrate that activated factor XIII, through its cross-linking of α2-antiplasmin to fibrin, also regulates fibrinolysis in experimental PE. 17 Mutch et al 27 found that PAI-1, TAFI, and α2-antiplasmin had complementary effects on fibrinolysis, although α2-antiplasmin had the dominant role. In comparative in vivo studies, Dewerchin et al 28 showed that α2-antiplasmin was more potent than PAI-1 for suppressing dissolution of experimental pulmonary emboli. This is consistent with our finding that dissolution of experimental pulmonary emboli is restricted by the effects of α2-antiplasmin and not by an inability of the endogenous plasminogen activation system to generate plasmin.
These studies were performed in a humanized model to enhance their relevance for human PE. Still, even meticulous animal models may not fully simulate the complexity of human illnesses. Although these studies in PE, and others in ischemic stroke, show that α2-antiplasmin-I is not associated with significant bleeding risk, the safety of this approach for humans will need to be confirmed. 15, 29 Finally, these studies examined the effects of α2-antiplasmin inactivation on acute PE; its effect on subacute or chronic PE remains unknown.
Although equipotent in dissolving pulmonary emboli, α2-antiplasmin inactivation and pharmacological doses of r-tPA had divergent effects on fibrinogen degradation and bleeding. Low-dose r-tPA has minimal effects, but therapeutic doses of r-tPA consume fibrinogen and other coagulation factors, and enhance bleeding. [30] [31] [32] These effects are primarily attributed to the fact that therapeutic doses of r-tPA generate large amounts of plasmin to overcome the effects of α2-antiplasmin and deplete coagulation proteins, which reduces hemostatic potential. 33 In the presence of massive plasminemia, α2-antiplasmin may have a protective effect by helping to prevent fibrinogen and coagulation factor depletion. 33 In contrast, α2-antiplasmin inactivation prolongs the half-life of plasmin generated at the site of the fibrin thrombus, but does not interfere with plasmin inactivation in the circulation by α2-macroglobulin and potentially other inhibitors. Even when plasmin generation is slightly enhanced by lowdose r-tPA in the presence of α2-antiplasmin inactivation, there is not a signal of enhanced fibrinogen consumption or of bleeding. This is consistent with recent studies of experimental ischemic stroke where α2-antiplasmin inactivation has been shown to reduce bleeding while enhancing dissolution of middle cerebral artery thrombi, reducing brain infarction, and increasing survival. 15, 29 This argues that the main effect of α2-antiplasmin inactivation is to enhance local fibrinolysis of thrombi without triggering consumption of coagulation factors.
Despite anticoagulation, inadequate fibrinolysis in patients with acute PE may contribute to acute mortality and longer-term disability and death. The present studies suggest that even after the onset of pulmonary embolism, therapeutic modulation of α2-antiplasmin activity may prove an effective strategy to enhance endogenous or physiological fibrinolysis without significantly increasing the bleeding risk. Initial studies are now underway in a National Institutes of Health-supported trial to evaluate the safety and biomarker efficacy of α2-antiplasmin inactivation in humans.
